Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf 'unlimited' therapeutic agent: Results from the acute myocardial infarction first-in-man study

Postepy w Kardiologii Interwencyjnej

Volumn 11, Issue 2, 2015, Pages 100-107

  Musialek, Piotr ^a,b   Mazurek, Adam ^a,b   Jarocha, Danuta ^c   Tekieli, Lukasz ^a,b   Szot, Wojciech ^b   Kostkiewicz, Magdalena ^b   Banys, R Pawel ^b   Urbanczyk, Malgorzata ^b   Kadzielski, Andrzej ^a   Trystula, Mariusz ^b   Kijowski, Jacek ^c   Zmudka, Krzysztof ^a,b   Podolec, Piotr ^a,b   Majka, Marcin ^c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Acute myocardial infarction; Feasibility; First in man; Human umbilical cord matrix; Myocardial regeneration; Safety; Wharton's jelly mesenchymal stem cells

Indexed keywords

AMOXICILLIN; ANTIHISTAMINIC AGENT; CELL THERAPY AGENT; CREATINE KINASE MB; PARACETAMOL; STEROID; TROPONIN T;

ACUTE HEART INFARCTION; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FEVER; FIRST IN HUMAN STUDY; FOLLOW UP; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART MUSCLE PERFUSION; HOLTER MONITORING; HUMAN; HUMAN CELL; INJECTION SITE INFLAMMATION; INTRAVENOUS CATHETER; MALE; MESENCHYMAL STROMA CELL; MUSCLE REGENERATION; MYOCARDIAL REGENERATION; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; STEM CELL TRANSPLANTATION; STEROID THERAPY; WHARTON JELLY; WHARTON JELLY MESENCHYMAL STEM CELL;

EID: 84936935800     PISSN: 17349338     EISSN: 18974295     Source Type: Journal    
DOI: 10.5114/pwki.2015.52282     Document Type: Article

References (45)

1. Gyöngyösi M, Wojakowski W, Lemarchand P, et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 2015; 116: 1346-60.
2. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells 2004; 22: 1330-7.
3. Badimon L, Vilahur G. Experimental cell therapy: The search for the best stem cell continues. J Am Coll Cardiol 2014; 64: 1695-7.
4. Corrao S, LaRocca G, LoIacono M, et al. New frontiers in regenerative medicine in cardiology: The potential of Wharton's jelly mesenchymal stem cells. Curr Stem Cell Res Ther 2013; 8: 39-45.
5. Can A, Karahuseyinoglu S. Human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells 2007; 25: 2886-95.
6. Bongso A, Fong CY. The therapeutic potential, challenges and future clinical directions of stem cells from the Wharton's jelly of the human umbilical cord. Stem Cell Rev 2013; 9: 226-40.
7. Swamynathan P, Venugopal P, Kannan S, et al. Are serum-free and xeno-free culture conditions ideal for large scale clinical grade expansion of Wharton's jelly derived mesenchymal stem cells? A comparative study. Stem Cell Res Ther 2014; 5: 88.
8. Wu KH, Zhou B, Yu CT, et al. Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. Ann Thorac Surg 2007; 83: 1491-8.
9. Zhang W, Liu XC, Yang L. Wharton's jelly-derived mesenchymal stem cells promote myocardial regeneration and cardiac repair after miniswine acute myocardial infarction. Coron Artery Dis 2013; 24: 549-58.
10. Santos Nascimento D, Mosqueira D, Sousa LM, et al. Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms. Stem Cell Res Ther 2014; 5: 5.
11. Gao LR, Zhang NK, Ding QA, et al. Common expression of stemness molecular markers and early cardiac transcription factors in human Wharton's jelly-derived mesenchymal stem cells and embryonic stem cells. Cell Transplant 2013; 22: 1883-900.
12. Lupu M, Khalil M, Andrei E, et al. Integration properties of Wharton's jelly-derived mesenchymal stem cells into ventricular slices of murine hearts. Cell Physiol Biochem 2011; 28: 63-76.
13. Yannarelli G, Dayan V, Pacienza N, et al. Human umbilical cord perivascular cells exhibit enhanced cardiomyocyte reprogramming and cardiac function after experimental acute myocardial infarction. Cell Transplant 2013; 22: 1651-66.
14. Musialek P, Tekieli L, Kostkiewicz M, et al. Randomized transcoronary delivery of CD34+ cells with perfusion versus stop-flow method in patients with recent myocardial infarction: Early cardiac retention of 99mTc-labeled cells activity. J Nucl Cardiol 2011; 18: 104-16.
15. Musialek P, Tekieli L, Kostkiewicz M, et al. Infarct size determines myocardial uptake of CD34+ cells in the peri-infarct zone: Results from a study of 99mTc-extametazime-labeled cell visualization integrated with cardiac magnetic resonance infarct imaging. Circ Cardiovasc Imaging 2013; 6: 320-8.
16. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage- specified biologics. J Am Coll Cardiol 2013; 62: 2454-6.
17. Tongers J, Losordo DW, Landmesser U. Stem and progenitor cell based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J 2011; 32: 1197-206.
18. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 2015; 116: 1413-30.
19. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355: 1730-5.
20. Houtgraaf JH, de Jong R, Kazemi K, et al. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ Res 2013; 113: 153-66.
21. Musialek P, Tracz W, Skotnicki AB, et al. Transcoronary stem cell delivery using physiological endothelium-targeting perfusion technique: The rationale and a pilot study involving a comparison with conventional over-the-wire balloon coronary occlusions in patients after recent myocardial infarction. Kardiol Pol 2006; 64: 489-98.
22. Musialek P, Kostkiewicz M, Banys RP, et al. Early myocardial engraftment of autologous CD34+ cells administered transcoronary via a physiological cell-delivery system. Eur J Nucl Med Mol Imaging 2008; 35: 1929-30.
23. Musialek P. Coronary thrombus management. In: Treatment strategies - interventional cardiology. Eeckhout E, Evangelista A, Holmes D, Leon MB, Stone GW (eds). Cambridge Research Centre, UK, 2012; 97-106.
24. Kacprzak M, Kidawa M, Zielinska M. Fever in myocardial infarction: Is it still common, is it still predictive? Cardiol J 2012; 19: 369-73.
25. Musialek P. TASTE-less endpoint of 30-day mortality (and some other issues with TASTE) in evaluating the effectiveness of thrombus aspiration in STEMI: not the "evidence" to change the current practice of routine consideration of manual thrombus extraction. State-of-the-art review. Kardiol Pol 2014; 72: 479-87.
26. Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012; 2: CD006536.
27. Iwasaki H, Kawamoto A, Ishikawa M, et al. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation 2006; 113: 1311-25.
28. Gao LR, Pei XT, Ding QA, et al. A critical challenge: dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction. Int J Cardiol 2013; 168: 3191-9.
29. Griffin MD, Ryan AE, Alagesan S, et al. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: What have we learned so far? Immunol Cell Biol 2013; 91: 40-51.
30. Lohan P, Coleman CM, Murphy JM, et al. Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned? Stem Cell Res Ther 2014; 5: 99.
31. Wojakowski W, Tendera M, Cybulski W, et al. Effects of intracoronary delivery of allogenic bone marrow-derived stem cells expressing heme oxygenase-1 on myocardial reperfusion injury. Thromb Haemost 2012; 108: 464-75.
32. Musialek P, Tracz W, Kostkiewicz M, et al. Visualisation of early engraftment of transcoronary applied CD34+ cells in the infarct border zone. Kardiol Pol 2008; 66: 73-7.
33. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. JAMA 2012; 308: 2369-79.
34. Tang Q, Chen Q, Lai X, et al. Malignant transformation potentials of human umbilical cord mesenchymal stem cells both spontaneously and via 3-methycholanthrene induction. PLoS One 2013; 8: E81844.
35. Weiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells 2008; 26: 2865-74.
36. Holley RJ, Tai G, Williamson AJ, et al. Comparative quantification of the surfaceome of human multipotent mesenchymal progenitor cells. Stem Cell Reports 2015; 4: 473-88.
37. Duya P, Bian Y, Chu X, et al. Stem cells for reprogramming: could hUMSCs be a better choice? Cytotechnology 2013; 65: 335-45.
38. Kadner A, Zund G, Maurus C, et al. Human umbilical cord cells for cardiovascular tissue engineering: A comparative study. Eur J Cardiothorac Surg 2004; 25: 635-41.
39. Breymann C, Schmidt D, Hoerstrup SP. Umbilical cord cells as a source of cardiovascular tissue engineering. Stem Cell Rev 2006; 2: 87-92.
40. Semenov OV, Breymann C. Mesenchymal stem cells derived from Wharton's jelly and their potential for cardio-vascular tissue engineering. Open Tissue Eng Regen Med J 2011; 4: 64-71.
41. Weymann A, Patil NP, Sabashnikov A, et al. Bioartificial heart: A human-sized porcine model - the way ahead. PLoS One 2014; 9: E111591.
42. Grieve SM, Bhindi R, Seow J, et al. Microvascular obstruction by intracoronary delivery of mesenchymal stem cells and quantification of resulting myocardial infarction by cardiac magnetic resonance. Circ Heart Fail 2010; 3: E5-e6.
43. Tang XL, Rokosh G, Sanganalmath SK, et al. Effects of intracoronary infusion of escalating doses of cardiac stem cells in rats with acute myocardial infarction. Circ Heart Fail 2015 May 20 [Epub ahead of print].
44. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and meta-analysis of clinical trials. PLoS One 2012; 7: E47559.
45. Kooreman NG, Ransohoff JD, Wu JC. Tracking gene and cell fate for therapeutic gain. Nature Mat 2014; 13: 106-9.